Coherus Biosciences | CHRS - Assets


Coherus Biosciences reported $191.18M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Akebia Therapeutics USD 342.13M 7.53M Sep/2026
ALKERMES USD 4.44B 42.4M Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
Amgen USD 96.05B 409M Sep/2026
Baxter International USD 19.41B 377M Sep/2026
Biogen USD 32.05B 32.5M Sep/2026
BioMarin Pharmaceutical USD 11.57B 154.21M Sep/2026
Bristol-Myers Squibb USD 88.77B 1.14B Sep/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Eli Lilly USD 148.07B 5.79B Sep/2026
Fujifilm JPY 6.1T 64.55B Sep/2026
Gilead Sciences USD 51.41B 2.05B Sep/2026
Ironwood Pharmaceuticals USD 290.59M 5.46M Sep/2026
Merck USD 132.77B 2.97B Sep/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Pacira USD 34.68B 33.44B Sep/2026
Perrigo USD 7.48B 124.6M Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
PTC Therapeutics USD 3.21B 42.76M Sep/2026
Regeneron Pharmaceuticals USD 44.41B 2.67B Sep/2026
Sarepta Therapeutics USD 3.17B 22.45M Sep/2026
Teva Pharmaceutical Industries USD 40.04B 185M Sep/2026
Vertex Pharmaceuticals USD 32.74B 5.31B Sep/2026
Xencor USD 770.5M 45.54M Sep/2026
Zoetis USD 15.09B 11M Sep/2026